Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN401583 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Neurotrophic Tyrosine Kinase, Receptor, Type 2 (NTRK2) (pTyr515) antibody
- Antibody type
- Polyclonal
- Description
- Immunoaffinity Chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
- Reactivity
- Human, Rat
- Host
- Rabbit
- Epitope
- pTyr515
- Vial size
- 50 μL
- Storage
- Store the antibody (in aliquots) at-20°C.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Associative Classification of Mammograms using Weighted Rules.
Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase.
BDNF-mediated enhancement of inflammation and injury in the aging heart.
Identification and characterization of compounds that potentiate NT-3-mediated Trk receptor activity.
Dua S, Singh H, Thompson HW
Expert systems with applications 2009 Jul 1;36(5):9250-9259
Expert systems with applications 2009 Jul 1;36(5):9250-9259
Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase.
Woronowicz A, Amith SR, De Vusser K, Laroy W, Contreras R, Basta S, Szewczuk MR
Glycobiology 2007 Jan;17(1):10-24
Glycobiology 2007 Jan;17(1):10-24
BDNF-mediated enhancement of inflammation and injury in the aging heart.
Cai D, Holm JM, Duignan IJ, Zheng J, Xaymardan M, Chin A, Ballard VL, Bella JN, Edelberg JM
Physiological genomics 2006 Feb 14;24(3):191-7
Physiological genomics 2006 Feb 14;24(3):191-7
Identification and characterization of compounds that potentiate NT-3-mediated Trk receptor activity.
Lewis MA, Hunihan L, Franco D, Robertson B, Palmer J, Laurent DR, Balasubramanian BN, Li Y, Westphal RS
Molecular pharmacology 2006 Apr;69(4):1396-404
Molecular pharmacology 2006 Apr;69(4):1396-404
No comments: Submit comment
No validations: Submit validation data